Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q1 2023 · 10-Q
Revenue$9.22M$9.22M−17.5% vs Q1 2022 Net Income$192.18K$192.18KN/M vs Q1 2022 EPS Diluted$0.01$0.01N/M vs Q1 2022 Operating Income-$1,531,678N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,525,469N/M Margins · derivedOperating margin-16.6%−5.0 pt vs Q1 2022
Net margin2.1%+14.5 pt vs Q1 2022
ended Mar 31, 2023 · filed May 12, 2023 · 42 d after period end